Interim analysis of the phase III ALPINE trial comparing Brukinsa to ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma to be reported at EHA 2021 virtual congress.-BeiGene

The abstract has also been selected by the Scientific Program Committee to be highlighted in the EHA2021 Virtual Press Briefing. Results from the interim analysis were based on 415 enrolled patients in the trial, including 207 on Brukinsa treatment and 208 on ibrutinib treatment. As previously announced, the ALPINE trial met its primary endpoint, with Brukinsa demonstrating non-inferiority in objective response rate (ORR) per investigator assessment and independent review committee (IRC), and superiority in ORR per investigator assessment. The trial also met a pre-specified secondary endpoint related to safety, with Brukinsa demonstrating a statistically significant lower risk of atrial fibrillation or flutter, compared to ibrutinib. More details on the ALPINE trial results will be provided by Peter Hillmen, MBChB, Ph.D., Professor of Experimental Haematology at University of Leeds and trial investigator, in an oral presentation (abstract code: LB1900) at EHA2021 on Friday, June 11 at 5:15 p.m. CEST (11:15 a.m. ET), as part of the Presidential Symposium.